Eli Lilly and Co

Industry: Major Drugs

Fortune Rank: 112

Eli Lilly & Co. is engaged in the discovery, development, manufacture and sale of pharmaceutical products. For the 9 months ended 9/30/05, net sales rose 5% to $10.77B. Net income fell 29% to $1.28B. Revenues reflect the strong performances of Zyprexa, Humalog, Gemzar and Evista and the recent launches of Strattera, Cialis and Forteo. Earnings were offset by an increase in asset impairment and restructuring charges.

Eli Lilly and Company discovers, develops, manufactures and sells pharmaceutical products. The Company also has an animal health business segment. The Company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico and 22 other countries. Eli Lilly and Company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. The Company's Neuroscience products consist of Zyprexa, Strattera, Prozac, Cymbalta, Permax, Symbyax, Sarafem and YentreveÔ. Endocrine products include Humalog, Humalog Mix 75/25, Humulin, Actos, Evista, Humatrope and Forteo. Oncology products consist of Gemzar and Alimta. Animal health products include Tylan, Rumensin, Coban, Monteban, Maxiban, Apralan, Micotil, Pulmotil, Surmax, Paylean and Optaflexx. Cardiovascular agents consist of ReoPro and Xigris. Anti-infectives include Ceclor and Vancocin HCl.

Eli Lilly and Co

Eli Lilly and Co is a Fortune 500 company. In 2010 Eli Lilly and Co was ranked number 112 on the Fortune 500 list, making it the 112th largest company in the United States when judged by revenue.

Eli Lilly and Co achieved revenue of $21,836.00 million in 2010 and earned a profit of $4,328.80 million.

Eli Lilly and Co' rank improves

The company ranking improved in 2010, moving up the Fortune 500 list to 112th compared to 122nd in 2009. This was based on its 2009 revenue of $20,378 million (a change of 1 million compared to 2010) and profits of $-2,072 million (a change of $6 million compared to 2009).

Another point of view

To many investors, profits are more important than the revenue a company earns. If the Fortune 500 was ranked by profits instead of revenue then Eli Lilly and Co would be ranked 34th rather than 112th due to its profits of $4,329 in 2010.

Eli Lilly and Co Revenue* Profit* Fortune Ranking

* US$ Million

USPages Latest Business News At A Glance Business Shortcuts